Clinical Pediatrics

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for free access to the SAGE eReference platform!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
0009922807306994v1
47/2/160    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gooding, J.
Right arrow Articles by Lacroix, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gooding, J.
Right arrow Articles by Lacroix, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
First published on September 27, 2007, doi:10.1177/0009922807306994

Clinical Pediatrics 2008;47:160.

A more recent version of this article appeared on March 1, 2008

Article

The Cost and Safety of Multidose Use of Palivizumab Vials

Julie Gooding, MD1*, Aaron Millage, MD, Anna-Kathryn Rye, MD2, and Robin Lacroix, MD3

1 Greenville Hospital System/ Department of Pediatrics
2 St. Jude's Children's Hospital
3 Greenville Hospital System/Pediatric Infectious Diseases

* To whom correspondence should be addressed. E-mail: jgooding{at}ghs.org.


  Abstract
Palivizumab is an antirespiratory syncytial virus humanized murine monoclonal antibody that has been shown to reduce the frequency of hospitalization rates of preterm infants infected with respiratory syncytial virus. The United States Food and Drug Administration has approved palivizumab for single-vial dosage; however, if multidose use of single-use vials is proven safe, significant cost savings for respiratory syncytial virus prophylaxis would result. A total of 446 palivizumab vials administered to patients during the respiratory syncytial virus seasons of 2004-2006 were examined for bacterial contamination. One single-use vial showed growth of multiple organisms, and all multidose-use vials were culture negative. The cost benefits of multi-dose palivizumab vials netted a potential average savings of $37 410 per year in this institution. This study suggests that multidose distribution is a possible solution for cost savings with no increased risk to patients. Secondary to the low incidence of complications, the safety of this practice will require a larger study.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?